glutathione cas number 1200mg — 1200mg/vial Reference Standard Free Acid Sigma-Aldrich ʟ-Glutathione reduced, CAS 70-18-8,

CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head

Anti-inflammatory activity: Demonstrates reduction in inflammatory markers in laboratory models

doi: 10.1371/journal.pmed.1001321 56

[DOI] [PMC free article] [PubMed] [Google Scholar] 5.Serini S, Ottes Vasconcelos R, Fasano E, Calviello G